Results 11 to 20 of about 17,756 (247)
Leukemia, 2022 Radioimmunotherapy (RIT) has long been pursued to improve outcomes in acute leukemia and higher-risk myelodysplastic syndrome (MDS). Of increasing interest are alpha-particle-emitting radionuclides such as astatine-211 (211At) as they deliver large ...
G. S. Laszlo +12 more
semanticscholar +4 more sources
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells [PDF]
Nature Communications, 2022 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with poor outcomes with conventional therapy. Nearly 100% of BPDCNs overexpress interleukin 3 receptor subunit alpha (CD123).
Tian-Yu Cai +32 more
semanticscholar +7 more sources
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies [PDF]
Cancers, 2019 The interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, is widely overexpressed in various hematological malignancies, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, hairy cell leukemia, Hodgkin ...
U. Testa, E. Pelosi, G. Castelli
semanticscholar +4 more sources
CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
International Journal of Molecular Sciences, 2023 In spite of consistent progress at the level of basic research and of clinical treatment, acute myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric patients. To improve the outcomes of these patients, it is necessary to
E. Pelosi, G. Castelli, U. Testa
semanticscholar +2 more sources
Drug Delivery, 2017 A novel niosomal delivery system was designed and investigated for the targeted delivery of daunorubicin (DNR) against acute myeloid leukemia (AML). Anti-CD123 antibodies conjugated to Mal-PEG2000-DSPE were incorporated into normal niosomes (NS) via a ...
Fu-rong Liu +7 more
doaj +2 more sources
Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia
Human Vaccines & Immunotherapeutics, 2020 The IL-3 alpha chain receptor (CD123) is a cell surface protein that is widely expressed by various subtypes of acute leukemia, including acute myeloid leukemia (AML), acute lymphoblastic leukemia and blastic plasmacytoid dendritic cell neoplasm. Notably,
Ibrahim Aldoss +3 more
doaj +2 more sources
Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones [PDF]
Journal of Hematology & Oncology, 2016 Background Acute myeloid leukemia (AML) is a heterogeneous clonal disorder presenting with accumulation of proliferating undifferentiated blasts. Xenograft transplantation studies have demonstrated a rare population of leukemia-initiating cells called ...
Adhra Al-Mawali, David Gillis, Ian Lewis
doaj +2 more sources
CD123-Targeted Nano-Curcumin Molecule Enhances Cytotoxic Efficacy in Leukemic Stem Cells
Nanomaterials, 2021 Acute myeloblastic leukemia (AML) is a disease with a high rate of relapse and drug resistance due to the remaining leukemic stem cells (LSCs). Therefore, LSCs are specific targets for the treatment of leukemia.
Wariya Nirachonkul +7 more
doaj +2 more sources
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo [PDF]
Journal for ImmunoTherapy of Cancer, 2020 Background Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies ...
Pablo Menendez +23 more
doaj +4 more sources
CD123‐targeting immunotherapeutic approaches in acute myeloid leukaemia
British Journal of HaematologyTreatment of relapsed or refractory acute myeloid leukaemia (AML) has remained a significant challenge, with limited available targeted immunotherapies.
Alexandra Dreyzin +2 more
semanticscholar +2 more sources